Patent · US Active

Tau immunotherapy

US10752679B2 · kind B2 · utility

9Cited by
3References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 2, 2017
Grant dateAug 25, 2020
Priority date—
Expiry dateMay 2, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.